Alta Bioequities sells 11,803 Krystal Biotech shares

Accepted by SEC EDGAR 03/03/2026 - 06:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Krystal Biotech director-linked entity sells shares under trading plan

Alta Bioequities, L.P., an entity associated with Krystal Biotech director Daniel Janney, sold a total of 11,803 shares of the company’s common stock in two open-market transactions on February 27, 2026, at weighted average prices of $275.4487 and $276.1665 per share.

The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 25, 2025, which is scheduled to terminate on November 5, 2026, subject to early termination. Alta Bioequities, L.P. continued to hold 73,293 shares after these transactions.

Insider Trade Summary

Net Seller: 11,803 shares

Net Sell 2 txns

Insider JANNEY DANIEL

Role Director

Sold 11,803 shs ($3.25M)

Share of Position Sold 13.9%

Type	Security	Shares	Price	Value
Sale	Common Stock	9,430	$275.4487	$2.60M
Sale	Common Stock	2,373	$276.1665	$655K

Holdings After Transaction: Common Stock — 73,293 shares (Indirect, Directly beneficially owned by Alta Bioequities, L.P.)

Holdings Before and After: Common Stock, 85,096 to 73,293 shares (Indirect, Directly beneficially owned by Alta Bioequities, L.P.)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

1. F1. The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
2. F2. The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
3. F3. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
4. F4. The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Krystal Biotech (KRYS) disclose in this Form 4?

Krystal Biotech disclosed that Alta Bioequities, L.P., an entity associated with director Daniel Janney, sold 11,803 shares of common stock in open-market transactions on February 27, 2026, at weighted average prices around $275–$276 per share under a Rule 10b5-1 plan.

Who actually sold the Krystal Biotech (KRYS) shares in this filing?

The shares were sold by Alta Bioequities, L.P., whose general partner is Alta Bioequities Management, LLC. Daniel Janney is Managing Director of that general partner and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest, according to the filing’s footnote.

How many Krystal Biotech (KRYS) shares were sold and at what prices?

Alta Bioequities, L.P. sold 9,430 shares at a weighted average price of $275.4487 and 2,373 shares at a weighted average price of $276.1665, totaling 11,803 shares. The trades occurred within narrower price ranges between approximately $275 and $276.4924 per share.

Was the Krystal Biotech (KRYS) insider sale part of a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on November 25, 2025. That plan is scheduled to terminate on November 5, 2026, subject to early termination, including once all covered shares have been sold under the plan’s terms.

How many Krystal Biotech (KRYS) shares did Alta Bioequities, L.P. hold after the sale?

After the February 27, 2026 transactions, Alta Bioequities, L.P. held 73,293 shares of Krystal Biotech common stock. This post-transaction balance reflects the reported open-market sales totaling 11,803 shares executed under the Rule 10b5-1 trading plan described in the filing.

What price detail ranges are disclosed for the Krystal Biotech (KRYS) insider sales?

For the 9,430-share sale, trades occurred between $275 and $275.986 per share, with a weighted average of $275.4487. For the 2,373-share sale, trades ranged from $276 to $276.4924, with a weighted average of $276.1665, according to the filing’s footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JANNEY DANIEL

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		S(1)		9,430	D	$275.4487(2)	75,666	I	Directly beneficially owned by Alta Bioequities, L.P.(3)
Common Stock	02/27/2026		S(1)		2,373	D	$276.1665(4)	73,293	I	Directly beneficially owned by Alta Bioequities, L.P.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

2. The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

4. The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Daniel Janney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.